跳转到内容

伏妥昔单抗：修订间差异

维基百科，自由的百科全书
以互动方式浏览历史
←上一版本下一版本→
删除的内容 添加的内容
可视化wikitext
无编辑摘要
无编辑摘要
第35行： 第35行：
}}
}}


'''伏妥昔单抗'''（INN：futuximab，开发代号：'''992 DS'''）是一种嵌合单克隆抗体，设计用于治疗癌症。<ref>[http://www.ama-assn.org/resources/doc/usan/x-pub/futuximab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab], ''[[American Medical Association]]''.</ref>它充当免疫调节剂并与 HER1 结合。<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf }}</ref><ref>{{cite journal |vauthors=Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD |title=Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models |journal=J. Neurooncol. |volume=138 |issue=3 |pages=489–498 |date=July 2018 |pmid=29564747 |doi=10.1007/s11060-018-2832-6 |pmc=5999169 }}</ref>
'''伏妥昔单抗'''（[[INN]]：futuximab，开发代号：'''992 DS'''）是一种嵌合[[单克隆抗体]]，设计用于治疗[[癌症]]。<ref>[http://www.ama-assn.org/resources/doc/usan/x-pub/futuximab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab], ''[[American Medical Association]]''.</ref>它充当免疫调节剂并与 HER1 结合。<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf }}</ref><ref>{{cite journal |vauthors=Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD |title=Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models |journal=J. Neurooncol. |volume=138 |issue=3 |pages=489–498 |date=July 2018 |pmid=29564747 |doi=10.1007/s11060-018-2832-6 |pmc=5999169 }}</ref>


该药物由[[Symphogen]]开发。
该药物由{{le|Symphogen|Symphogen}}开发。


== 参考资料 ==
== 参考资料 ==

2024年3月6日 (三) 16:12的版本

伏妥昔单抗
单克隆抗体
种类完整抗体
目標HER1
臨床資料
其他名稱992 DS
ATC碼
  • 未分配
识别信息
CAS号1310460-85-5
ChemSpider
  • none
UNII
化学信息
化学式C6468H10002N1724O2055S46
摩尔质量146,269.94 g·mol−1

伏妥昔单抗（INN：futuximab，开发代号：992 DS）是一种嵌合单克隆抗体，设计用于治疗癌症。[1]它充当免疫调节剂并与 HER1 结合。[2][3]

该药物由Symphogen（英语：Symphogen）开发。

参考资料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.
  2. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2). 
  3. ^ Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J. Neurooncol. July 2018, 138 (3): 489–498. PMC 5999169 可免费查阅. PMID 29564747. doi:10.1007/s11060-018-2832-6. 
检索自“https://zh.wikipedia.org/zhwiki/w/index.php?title=伏妥昔单抗&oldid=81797990”